Indian drugmaker Biocon has partnered with Japanese drug firm Eisai Pharma to market the latter's anti-ulcer drug rabeprazole in India.
Eisai’s brand is sold as Parit and its combination drug Parit-D. The Japanese firm has terminated its earlier co-marketing arrangement with GSK in India, with sources saying Eisai was disappointed with its partner's brand development and sales push.
The dollar pulled away from 4 month lows against currency basket as solid data backed expectations for more US Interest rate hikes this year, sterling was knocked by concern about Britain's impending exit from the European Union.
Eisai’s brand is sold as Parit and its combination drug Parit-D. The Japanese firm has terminated its earlier co-marketing arrangement with GSK in India, with sources saying Eisai was disappointed with its partner's brand development and sales push.
The dollar pulled away from 4 month lows against currency basket as solid data backed expectations for more US Interest rate hikes this year, sterling was knocked by concern about Britain's impending exit from the European Union.
No comments:
Post a Comment